Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.25964 http://scihub22266oqcxt.onion/10.1002/jmv.25964 32369191!7267594!32369191     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Virol 2020 ; 92 (10): 2042-2049 Nephropedia Template TP {{tp|p=32369191|t=2020. Tocilizumab for the treatment of severe coronavirus disease 2019 |pdf=|usr=}}{{32369191}} gab.com Text Tocilizumab for the treatment of severe coronavirus disease 2019 JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32369191 #FOAvip Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up. Twenty-five patients were included, median age was 58 years (interquartile range, 50-63) and the majority were males (92%). Co-morbidities included diabetes mellitus (48%), chronic kidney disease (16%), and cardiovascular disease (12%). Fever (92%), cough (84%), and dyspnea (72%) were the commonest presenting symptoms. All patients received at least two concomitant investigational antiviral agents. Median oral temperature was on day 1, 3, and 7 was 38.0 degrees C, 37.3 degrees C (P = .043), and 37.0 degrees C (P = .064), respectively. Corresponding median C-reactive protein was 193 and 7.9 mg/L (P < .0001) and <6 mg/L (P = .0001). Radiological improvement was noted in 44% of patients by day 7% and 68% by day 14. Nine patients (36%) were discharged alive from intensive care unit and three (12%) died. The proportion of patients on invasive ventilation declined from (84%) at the time of tocilizumab initiation to 60% on day 7 (P = .031) and 28% on day 14 (P = .001). The majority (92%) of patients experienced at least one adverse event. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilatory support requirements. Given the study's limitations, the results require assessment in adequately powered randomized controlled trials. Twit Text FOAVip Tocilizumab for the treatment of severe coronavirus disease 2019 ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32369191 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32369191 #FOAvip English Wikipedia <ref>{{Cite pmid|32369191}}</ref> Tocilizumab for the treatment of severe coronavirus disease 2019 #MMPMID32369191 Alattar R; Ibrahim TBH; Shaar SH; Abdalla S; Shukri K; Daghfal JN; Khatib MY; Aboukamar M; Abukhattab M; Alsoub HA; Almaslamani MA; Omrani AS J Med Virol 2020[Oct]; 92 (10): 2042-2049 PMID32369191show ga Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up. Twenty-five patients were included, median age was 58 years (interquartile range, 50-63) and the majority were males (92%). Co-morbidities included diabetes mellitus (48%), chronic kidney disease (16%), and cardiovascular disease (12%). Fever (92%), cough (84%), and dyspnea (72%) were the commonest presenting symptoms. All patients received at least two concomitant investigational antiviral agents. Median oral temperature was on day 1, 3, and 7 was 38.0 degrees C, 37.3 degrees C (P = .043), and 37.0 degrees C (P = .064), respectively. Corresponding median C-reactive protein was 193 and 7.9 mg/L (P < .0001) and <6 mg/L (P = .0001). Radiological improvement was noted in 44% of patients by day 7% and 68% by day 14. Nine patients (36%) were discharged alive from intensive care unit and three (12%) died. The proportion of patients on invasive ventilation declined from (84%) at the time of tocilizumab initiation to 60% on day 7 (P = .031) and 28% on day 14 (P = .001). The majority (92%) of patients experienced at least one adverse event. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilatory support requirements. Given the study's limitations, the results require assessment in adequately powered randomized controlled trials. |*COVID-19 Drug Treatment[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |C-Reactive Protein/analysis[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Qatar[MESH] |Respiration, Artificial[MESH]Tocilizumab for the treatment of severe coronavirus disease 2019 (epmc).pdf DeepDyve Pubget Overpricing